Ken Griffin Eiger Bio Pharmaceuticals, Inc. Put Options Transaction History

Citadel Advisors LLC

4 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q4 2023 Feb 14, 2024	BUY	$0.21 - $0.43 $42 - $86	200 New	200 $0
Q1 2023 May 15, 2023	SELL	$0.89 - $2.52 $22,873 - $64,764	-25,700 Reduced 65.73%	13,400 $12,000
Q4 2022 Feb 14, 2023	BUY	$1.02 - $7.48 $28,866 - $211,684	28,300 Added 262.04%	39,100 $46,000
Q3 2022 Nov 14, 2022	BUY	$6.04 - $9.66 $65,232 - $104,328	10,800 New	10,800 $81,000

748K

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $418M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.